<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01185301</url>
  </required_header>
  <id_info>
    <org_study_id>M12-073</org_study_id>
    <secondary_id>2010-019514-24</secondary_id>
    <nct_id>NCT01185301</nct_id>
  </id_info>
  <brief_title>Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)</brief_title>
  <acronym>CONCERTO</acronym>
  <official_title>A Double-Blind, Randomized, Parallel-Arm, Multicenter Study to Determine the Dose Response of Methotrexate (MTX) in Combination Therapy With Adalimumab in Subjects With Early Rheumatoid Arthritis (CONCERTO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of different doses of methotrexate
      (MTX) when taken with adalimumab in subjects with early rheumatoid arthritis (RA).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With 28-Joint Disease Activity Score of C-reactive Protein (DAS28[CRP]) Low Disease Activity at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>Percentage of participants achieving low disease activity as defined by a clinical response (DAS28[CRP] &lt; 3.2). The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With DAS28(CRP) Remission at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>Disease remission was defined as a disease activity score, based on CRP, for 28 joints that was &lt; 2.6 (DAS28[CRP] &lt; 2.6). The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With American College of Rheumatology (ACR) 20 Criteria Response at Week 26</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>Response, as defined by ACR 20 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 20% improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Disability Index of the Health Assessment Questionnaire
Acute phase reactant value (C-reactive protein).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With American College of Rheumatology (ACR) 50 Criteria Response at Week 26</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>Response, as defined by ACR 50 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 50% improvement in tender joint count; ≥ 50% improvement in swollen joint count; and ≥ 50% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Disability Index of the Health Assessment Questionnaire
Acute phase reactant value (C-reactive protein).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With American College of Rheumatology (ACR) 70 Criteria Response at Week 26</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>Response, as defined by ACR 70 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 70% improvement in tender joint count; ≥ 70% improvement in swollen joint count; and ≥ 70% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Disability Index of the Health Assessment Questionnaire
Acute phase reactant value (C-reactive protein).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With American College of Rheumatology (ACR) 90 Criteria Response at Week 26</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>Response, as defined by ACR 90 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 90% improvement in tender joint count; ≥ 90% improvement in swollen joint count; and ≥ 90% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Disability Index of the Health Assessment Questionnaire
Acute phase reactant value (C-reactive protein).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With American College of Rheumatology (ACR) 100 Criteria Response at Week 26</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>Response, as defined by ACR 100 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 100% improvement in tender joint count; ≥ 100% improvement in swollen joint count; and ≥ 100% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Disability Index of the Health Assessment Questionnaire
Acute phase reactant value (C-reactive protein).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 26</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of &lt; 0.5. Negative change from Baseline in the overall score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) ≤ -0.22 at Week 26</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. The minimal clinically important difference (MCID) defined for the HAQ-DI is a change from Baseline of ≥ 0.22. HAQ remission indicating normal physical function is defined by HAQ-DI score of &lt; 0.5. Negative change from Baseline in the overall score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Modified Total Sharp Score (mTSS) at Week 26</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>The modified Total Sharp Score (mTSS) is a measure of change in joint health from digitized images of radiographs of hands and feet. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With No Radiographic Progression at Week 26</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>&quot;No radiographic progression&quot; was defined as a change from Baseline in modified Total Sharp Score (mTSS) at Week 26 of ≤ 0.5. mTSS is a measure of change in joint health from digitized images of radiographs of hands and feet. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Simplified Disease Activity Index (SDAI) Remission at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>SDAI is a measure of disease activity derived as follows: SDAI = SJC28 + TJC28 + GH (cm) + PhGA (cm) + CRP (mg/dL), where TJC28 and SJC28 represent total tender joint count and total swollen joint count, respectively, based on 28 joints (including the left and right side of the body), GH = Patient's Global Assessment of Disease Activity, and PhGA = Physician's Global Assessment of Disease Activity (both measured on a visual analogue scale with a range of 0 [none] to 10 [severe]), and CRP is C-reactive protein measured in mg/dL. SDAI total score = 0 to 86. SDAI ≤ 3.3 indicates disease remission, &gt; 3.4 to 11 = low disease activity, &gt; 11 to 26 = moderate disease activity, and &gt; 26 = high disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Disease Activity Index (CDAI) Remission at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>CDAI is a measure of disease activity derived as follows: CDAI = SJC28 + TJC28 + GH (cm) + PhGA (cm) where TJC28 and SJC28 represent total tender joint count and total swollen joint count, respectively, based on 28 joints (including the left and right side of the body), GH = Patient's Global Assessment of Disease Activity, and PhGA = Physician's Global Assessment of Disease Activity (both measured on a visual analogue scale with a range of 0 [none] to 10 [severe]). CDAI total score = 0 to 76. CDAI ≤ 2.8 indicates disease remission, &gt; 2.8 to 10 = low disease activity, &gt; 10 to 22 = moderate disease activity, and &gt; 22 = high disease activity.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">395</enrollment>
  <condition>Early Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>ADA + 2.5 mg MTX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.5 mg methotrexate (MTX) oral capsule weekly with 40 mg adalimumab (ADA) subcutaneous (SC) injection every other week (EOW) for 26 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADA + 5 mg MTX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADA + 10 mg MTX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADA + 20 mg MTX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MTX oral capsule dose escalation from 10 mg to 20 mg in 2.5 mg increments every other week (10 mg x 2 weeks, 12.5 mg x 2 weeks, 15 mg x 2 weeks, 17.5 mg x 2 weeks), then 20 mg for 18 weeks with 40 mg ADA SC injection EOW for 26 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>adalimumab</intervention_name>
    <description>Pre-filled syringe every other week</description>
    <arm_group_label>ADA + 2.5 mg MTX</arm_group_label>
    <arm_group_label>ADA + 5 mg MTX</arm_group_label>
    <arm_group_label>ADA + 10 mg MTX</arm_group_label>
    <arm_group_label>ADA + 20 mg MTX</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>weekly oral capsule dosing</description>
    <arm_group_label>ADA + 2.5 mg MTX</arm_group_label>
    <arm_group_label>ADA + 5 mg MTX</arm_group_label>
    <arm_group_label>ADA + 10 mg MTX</arm_group_label>
    <arm_group_label>ADA + 20 mg MTX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects at least 18 years of age

          -  Subject has a diagnosis of Rheumatoid Arthritis (RA) as defined by either the
             1987-revised American College of Rheumatology (ACR) classification criteria or the new
             ACR/ European League Against Rheumatism (EULAR) diagnostic criteria for RA 2010 and
             has a disease duration of less than 1 year from diagnosis by a licensed health care
             provider

          -  Subject must meet the following criteria:

               1. Disease Activity Score of C-reactive Protein (DAS28[CRP]) ≥ 3.2 (at the Baseline
                  visit only)

               2. At least 6 swollen joints out of 66 assessed (at the Screening and Baseline
                  visits)

               3. At least 8 tender joints out of 68 assessed (at the Screening and Baseline
                  visits)

               4. C-reactive protein (CRP) ≥ 1.5 mg/dL (at the Screening visit only), or
                  erythrocyte sedimentation rate (ESR) ≥ 28 mm/1h (at the Screening and Baseline
                  visits)

               5. Fulfill at least one of the following three criteria: Rheumatoid Factor (RF)
                  positive, have at least 1 bony erosion, anti-cyclic citrullinated peptide
                  (anti-CCP) antibody positive

          -  Subject is judged to be in good health as determined by the Principal Investigator
             based upon the results of medical history, laboratory profile, physical examination,
             chest x-ray (CXR), and a 12-lead electrocardiogram (ECG) performed during Screening

        Exclusion Criteria:

          -  Subject has previous exposure to any systemic biologic therapy including adalimumab

          -  Subject has been previously treated with greater than 1 disease modifying
             antirheumatic drugs (DMARDs) or with methotrexate (MTX)

          -  Subject has undergone joint surgery within the preceding two months (at joints to be
             assessed within the study)

          -  Subject has chronic arthritis diagnosed before age 17 years

          -  History of invasive infection (e.g., listeriosis and histoplasmosis), chronic or
             active Hepatitis C infection, human immunodeficiency virus (HIV) infection,
             immunodeficiency syndrome, chronic recurring infections or active tuberculosis (TB)

          -  Hepatitis B virus: hepatitis B surface antigen (HBs Ag) positive (+) or detected
             sensitivity on the hepatitis B virus DNA (HBV DNA) polymerase chain reaction (PCR)
             qualitative test

          -  Infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days
             prior to the Baseline Visit or oral anti-infectives within 14 days prior to the
             Baseline visit

          -  Female subject who is pregnant or breast-feeding or considering becoming pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dawn Carlson, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38973</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 41962</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 39260</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 45323</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38912</name>
      <address>
        <city>Hemet</city>
        <state>California</state>
        <zip>92543</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 39673</name>
      <address>
        <city>Victorville</city>
        <state>California</state>
        <zip>92395</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38909</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 40422</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38910</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44284</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38907</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38972</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 39670</name>
      <address>
        <city>Rock Island</city>
        <state>Illinois</state>
        <zip>61201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 42282</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38911</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 39672</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 42204</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 40651</name>
      <address>
        <city>Clifton</city>
        <state>New Jersey</state>
        <zip>07012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 41422</name>
      <address>
        <city>Freehold</city>
        <state>New Jersey</state>
        <zip>07728</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 41424</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 40463</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 42202</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44282</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 41423</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38971</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 39666</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 39643</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 45325</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 52042</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 40602</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44924</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1055AAF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44926</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425DTG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44925</name>
      <address>
        <city>Rosario, Santa Fe</city>
        <zip>S2000PBJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 47302</name>
      <address>
        <city>San Juan</city>
        <zip>J5402DIL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44928</name>
      <address>
        <city>Graz</city>
        <zip>80360</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44930</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44927</name>
      <address>
        <city>Vienna</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44934</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44935</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44933</name>
      <address>
        <city>Gilly</city>
        <zip>6060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44932</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43783</name>
      <address>
        <city>Edmonton</city>
        <zip>T5M 0H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43782</name>
      <address>
        <city>Winnipeg</city>
        <zip>R3A 1M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44937</name>
      <address>
        <city>Brno</city>
        <zip>63800</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 48962</name>
      <address>
        <city>Ceske Budejovice</city>
        <zip>37021</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44939</name>
      <address>
        <city>Ostrava</city>
        <zip>72200</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44936</name>
      <address>
        <city>Prague 2</city>
        <zip>128 50</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44938</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>686 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 48963</name>
      <address>
        <city>Zlin</city>
        <zip>76001</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44945</name>
      <address>
        <city>Berlin-Buch</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44941</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44942</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44944</name>
      <address>
        <city>Ratingen</city>
        <zip>40882</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44943</name>
      <address>
        <city>Zerbst</city>
        <zip>39261</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44946</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44982</name>
      <address>
        <city>Lodz</city>
        <zip>90-242</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 46584</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44984</name>
      <address>
        <city>Warsaw</city>
        <zip>02-118</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44983</name>
      <address>
        <city>Warsaw</city>
        <zip>02-256</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38975</name>
      <address>
        <city>Caguas</city>
        <zip>00725</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 40122</name>
      <address>
        <city>San Juan</city>
        <zip>00906-6312</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 39693</name>
      <address>
        <city>San Juan</city>
        <zip>00936-5067</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 38916</name>
      <address>
        <city>San Juan</city>
        <zip>00936-8344</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 39692</name>
      <address>
        <city>Vega Baja</city>
        <zip>00693</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44947</name>
      <address>
        <city>A Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44987</name>
      <address>
        <city>Elche (Alicante)</city>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44948</name>
      <address>
        <city>Oviedo (Asturias)</city>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 47782</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com</url>
  </link>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2010</study_first_submitted>
  <study_first_submitted_qc>August 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2010</study_first_posted>
  <results_first_submitted>September 11, 2013</results_first_submitted>
  <results_first_submitted_qc>September 11, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 15, 2013</results_first_posted>
  <last_update_submitted>September 11, 2013</last_update_submitted>
  <last_update_submitted_qc>September 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arthritis</keyword>
  <keyword>Erosion</keyword>
  <keyword>Humira</keyword>
  <keyword>Adalimumab</keyword>
  <keyword>Injection</keyword>
  <keyword>Rheumatoid</keyword>
  <keyword>Methotrexate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ADA + 2.5 mg MTX</title>
          <description>2.5 mg methotrexate (MTX) oral capsule weekly with 40 mg adalimumab (ADA) subcutaneous (SC) injection every other week (EOW) for 26 weeks</description>
        </group>
        <group group_id="P2">
          <title>ADA + 5 mg MTX</title>
          <description>5 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
        </group>
        <group group_id="P3">
          <title>ADA + 10 mg MTX</title>
          <description>10 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
        </group>
        <group group_id="P4">
          <title>ADA + 20 mg MTX</title>
          <description>MTX oral capsule dose escalation from 10 mg to 20 mg in 2.5 mg increments every other week (10 mg x 2 weeks, 12.5 mg x 2 weeks, 15 mg x 2 weeks, 17.5 mg x 2 weeks), then 20 mg for 18 weeks with 40 mg ADA SC injection EOW for 26 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="100"/>
                <participants group_id="P3" count="99"/>
                <participants group_id="P4" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="93"/>
                <participants group_id="P3" count="93"/>
                <participants group_id="P4" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ADA + 2.5 mg MTX</title>
          <description>2.5 mg methotrexate (MTX) oral capsule weekly with 40 mg adalimumab (ADA) subcutaneous (SC) injection every other week (EOW) for 26 weeks</description>
        </group>
        <group group_id="B2">
          <title>ADA + 5 mg MTX</title>
          <description>5 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
        </group>
        <group group_id="B3">
          <title>ADA + 10 mg MTX</title>
          <description>10 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
        </group>
        <group group_id="B4">
          <title>ADA + 20 mg MTX</title>
          <description>MTX oral capsule dose escalation from 10 mg to 20 mg in 2.5 mg increments every other week (10 mg x 2 weeks, 12.5 mg x 2 weeks, 15 mg x 2 weeks, 17.5 mg x 2 weeks), then 20 mg for 18 weeks with 40 mg ADA SC injection EOW for 26 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="98"/>
            <count group_id="B2" value="100"/>
            <count group_id="B3" value="99"/>
            <count group_id="B4" value="98"/>
            <count group_id="B5" value="395"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.0" spread="13.19"/>
                    <measurement group_id="B2" value="49.7" spread="13.14"/>
                    <measurement group_id="B3" value="52.1" spread="12.94"/>
                    <measurement group_id="B4" value="53.8" spread="14.41"/>
                    <measurement group_id="B5" value="51.9" spread="13.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="77"/>
                    <measurement group_id="B5" value="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="74"/>
                    <measurement group_id="B5" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>28-Joint Disease Activity Score of C-reactive Protein (DAS28[CRP])</title>
          <description>The DAS28(CRP) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission. Baseline values are presented for 96, 98, 95, 97 participants in the 2.5 mg, 5 mg, 10 mg, and 20 mg treatment groups, respectively.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.10" spread="0.921"/>
                    <measurement group_id="B2" value="6.22" spread="0.943"/>
                    <measurement group_id="B3" value="5.86" spread="0.971"/>
                    <measurement group_id="B4" value="5.91" spread="1.014"/>
                    <measurement group_id="B5" value="6.02" spread="0.970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Modified Total Sharp Score (mTSS)</title>
          <description>MTSS is a measure of change in joint health from digitized images of radiographs of hands and feet. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]). Baseline values are presented for 96, 98, 98, 95 participants in the 2.5 mg, 5 mg, 10 mg, and 20 mg treatment groups, respectively.</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.79" spread="12.849"/>
                    <measurement group_id="B2" value="8.60" spread="8.912"/>
                    <measurement group_id="B3" value="10.76" spread="13.017"/>
                    <measurement group_id="B4" value="10.55" spread="12.852"/>
                    <measurement group_id="B5" value="9.92" spread="12.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Health Assessment Questionnaire - Disability Index (HAQ-DI)</title>
          <description>HAQ-DI consists of 20 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week as: without any difficulty (0); with some difficulty (1); with much difficulty (2); unable to do (3). Scores on each task were summed and averaged to provide an overall score from 0 to 3, where 0=no disability and 3=very severe, high-dependency disability. Baseline values are presented for 96, 98, 97, 98 participants in the 2.5 mg, 5 mg, 10 mg, and 20 mg treatment groups, respectively.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.49" spread="0.737"/>
                    <measurement group_id="B2" value="1.57" spread="0.624"/>
                    <measurement group_id="B3" value="1.62" spread="0.667"/>
                    <measurement group_id="B4" value="1.58" spread="0.653"/>
                    <measurement group_id="B5" value="1.57" spread="0.670"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With 28-Joint Disease Activity Score of C-reactive Protein (DAS28[CRP]) Low Disease Activity at Week 26</title>
        <description>Percentage of participants achieving low disease activity as defined by a clinical response (DAS28[CRP] &lt; 3.2). The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
        <time_frame>Week 26</time_frame>
        <population>Intent-to-Treat population; participants with a missing response were imputed as non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA + 2.5 mg MTX</title>
            <description>2.5 mg methotrexate (MTX) oral capsule weekly with 40 mg adalimumab (ADA) subcutaneous (SC) injection every other week (EOW) for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>ADA + 5 mg MTX</title>
            <description>5 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>ADA + 10 mg MTX</title>
            <description>10 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
          <group group_id="O4">
            <title>ADA + 20 mg MTX</title>
            <description>MTX oral capsule dose escalation from 10 mg to 20 mg in 2.5 mg increments every other week (10 mg x 2 weeks, 12.5 mg x 2 weeks, 15 mg x 2 weeks, 17.5 mg x 2 weeks), then 20 mg for 18 weeks with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With 28-Joint Disease Activity Score of C-reactive Protein (DAS28[CRP]) Low Disease Activity at Week 26</title>
          <description>Percentage of participants achieving low disease activity as defined by a clinical response (DAS28[CRP] &lt; 3.2). The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
          <population>Intent-to-Treat population; participants with a missing response were imputed as non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9"/>
                    <measurement group_id="O2" value="44.0"/>
                    <measurement group_id="O3" value="56.6"/>
                    <measurement group_id="O4" value="60.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With DAS28(CRP) Remission at Week 26</title>
        <description>Disease remission was defined as a disease activity score, based on CRP, for 28 joints that was &lt; 2.6 (DAS28[CRP] &lt; 2.6). The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10.</description>
        <time_frame>Week 26</time_frame>
        <population>Intent-to-Treat population; participants with a missing response were imputed as non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA + 2.5 mg MTX</title>
            <description>2.5 mg methotrexate (MTX) oral capsule weekly with 40 mg adalimumab (ADA) subcutaneous (SC) injection every other week (EOW) for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>ADA + 5 mg MTX</title>
            <description>5 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>ADA + 10 mg MTX</title>
            <description>10 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
          <group group_id="O4">
            <title>ADA + 20 mg MTX</title>
            <description>MTX oral capsule dose escalation from 10 mg to 20 mg in 2.5 mg increments every other week (10 mg x 2 weeks, 12.5 mg x 2 weeks, 15 mg x 2 weeks, 17.5 mg x 2 weeks), then 20 mg for 18 weeks with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With DAS28(CRP) Remission at Week 26</title>
          <description>Disease remission was defined as a disease activity score, based on CRP, for 28 joints that was &lt; 2.6 (DAS28[CRP] &lt; 2.6). The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10.</description>
          <population>Intent-to-Treat population; participants with a missing response were imputed as non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6"/>
                    <measurement group_id="O2" value="32.0"/>
                    <measurement group_id="O3" value="37.4"/>
                    <measurement group_id="O4" value="44.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With American College of Rheumatology (ACR) 20 Criteria Response at Week 26</title>
        <description>Response, as defined by ACR 20 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 20% improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Disability Index of the Health Assessment Questionnaire
Acute phase reactant value (C-reactive protein).</description>
        <time_frame>Baseline, Week 26</time_frame>
        <population>Intent-to-Treat population; participants with a missing response were imputed as non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA + 2.5 mg MTX</title>
            <description>2.5 mg methotrexate (MTX) oral capsule weekly with 40 mg adalimumab (ADA) subcutaneous (SC) injection every other week (EOW) for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>ADA + 5 mg MTX</title>
            <description>5 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>ADA + 10 mg MTX</title>
            <description>10 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
          <group group_id="O4">
            <title>ADA + 20 mg MTX</title>
            <description>MTX oral capsule dose escalation from 10 mg to 20 mg in 2.5 mg increments every other week (10 mg x 2 weeks, 12.5 mg x 2 weeks, 15 mg x 2 weeks, 17.5 mg x 2 weeks), then 20 mg for 18 weeks with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With American College of Rheumatology (ACR) 20 Criteria Response at Week 26</title>
          <description>Response, as defined by ACR 20 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 20% improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Disability Index of the Health Assessment Questionnaire
Acute phase reactant value (C-reactive protein).</description>
          <population>Intent-to-Treat population; participants with a missing response were imputed as non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.3"/>
                    <measurement group_id="O2" value="74.0"/>
                    <measurement group_id="O3" value="76.8"/>
                    <measurement group_id="O4" value="79.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With American College of Rheumatology (ACR) 50 Criteria Response at Week 26</title>
        <description>Response, as defined by ACR 50 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 50% improvement in tender joint count; ≥ 50% improvement in swollen joint count; and ≥ 50% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Disability Index of the Health Assessment Questionnaire
Acute phase reactant value (C-reactive protein).</description>
        <time_frame>Baseline, Week 26</time_frame>
        <population>Intent-to-Treat population; participants with a missing response were imputed as non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA + 2.5 mg MTX</title>
            <description>2.5 mg methotrexate (MTX) oral capsule weekly with 40 mg adalimumab (ADA) subcutaneous (SC) injection every other week (EOW) for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>ADA + 5 mg MTX</title>
            <description>5 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>ADA + 10 mg MTX</title>
            <description>10 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
          <group group_id="O4">
            <title>ADA + 20 mg MTX</title>
            <description>MTX oral capsule dose escalation from 10 mg to 20 mg in 2.5 mg increments every other week (10 mg x 2 weeks, 12.5 mg x 2 weeks, 15 mg x 2 weeks, 17.5 mg x 2 weeks), then 20 mg for 18 weeks with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With American College of Rheumatology (ACR) 50 Criteria Response at Week 26</title>
          <description>Response, as defined by ACR 50 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 50% improvement in tender joint count; ≥ 50% improvement in swollen joint count; and ≥ 50% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Disability Index of the Health Assessment Questionnaire
Acute phase reactant value (C-reactive protein).</description>
          <population>Intent-to-Treat population; participants with a missing response were imputed as non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.9"/>
                    <measurement group_id="O2" value="51.0"/>
                    <measurement group_id="O3" value="53.5"/>
                    <measurement group_id="O4" value="62.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With American College of Rheumatology (ACR) 70 Criteria Response at Week 26</title>
        <description>Response, as defined by ACR 70 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 70% improvement in tender joint count; ≥ 70% improvement in swollen joint count; and ≥ 70% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Disability Index of the Health Assessment Questionnaire
Acute phase reactant value (C-reactive protein).</description>
        <time_frame>Baseline, Week 26</time_frame>
        <population>Intent-to-Treat population; participants with a missing response were imputed as non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA + 2.5 mg MTX</title>
            <description>2.5 mg methotrexate (MTX) oral capsule weekly with 40 mg adalimumab (ADA) subcutaneous (SC) injection every other week (EOW) for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>ADA + 5 mg MTX</title>
            <description>5 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>ADA + 10 mg MTX</title>
            <description>10 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
          <group group_id="O4">
            <title>ADA + 20 mg MTX</title>
            <description>MTX oral capsule dose escalation from 10 mg to 20 mg in 2.5 mg increments every other week (10 mg x 2 weeks, 12.5 mg x 2 weeks, 15 mg x 2 weeks, 17.5 mg x 2 weeks), then 20 mg for 18 weeks with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With American College of Rheumatology (ACR) 70 Criteria Response at Week 26</title>
          <description>Response, as defined by ACR 70 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 70% improvement in tender joint count; ≥ 70% improvement in swollen joint count; and ≥ 70% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Disability Index of the Health Assessment Questionnaire
Acute phase reactant value (C-reactive protein).</description>
          <population>Intent-to-Treat population; participants with a missing response were imputed as non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5"/>
                    <measurement group_id="O2" value="34.0"/>
                    <measurement group_id="O3" value="41.4"/>
                    <measurement group_id="O4" value="45.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With American College of Rheumatology (ACR) 90 Criteria Response at Week 26</title>
        <description>Response, as defined by ACR 90 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 90% improvement in tender joint count; ≥ 90% improvement in swollen joint count; and ≥ 90% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Disability Index of the Health Assessment Questionnaire
Acute phase reactant value (C-reactive protein).</description>
        <time_frame>Baseline, Week 26</time_frame>
        <population>Intent-to-Treat population; participants with a missing response were imputed as non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA + 2.5 mg MTX</title>
            <description>2.5 mg methotrexate (MTX) oral capsule weekly with 40 mg adalimumab (ADA) subcutaneous (SC) injection every other week (EOW) for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>ADA + 5 mg MTX</title>
            <description>5 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>ADA + 10 mg MTX</title>
            <description>10 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
          <group group_id="O4">
            <title>ADA + 20 mg MTX</title>
            <description>MTX oral capsule dose escalation from 10 mg to 20 mg in 2.5 mg increments every other week (10 mg x 2 weeks, 12.5 mg x 2 weeks, 15 mg x 2 weeks, 17.5 mg x 2 weeks), then 20 mg for 18 weeks with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With American College of Rheumatology (ACR) 90 Criteria Response at Week 26</title>
          <description>Response, as defined by ACR 90 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 90% improvement in tender joint count; ≥ 90% improvement in swollen joint count; and ≥ 90% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Disability Index of the Health Assessment Questionnaire
Acute phase reactant value (C-reactive protein).</description>
          <population>Intent-to-Treat population; participants with a missing response were imputed as non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="10.0"/>
                    <measurement group_id="O3" value="17.2"/>
                    <measurement group_id="O4" value="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With American College of Rheumatology (ACR) 100 Criteria Response at Week 26</title>
        <description>Response, as defined by ACR 100 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 100% improvement in tender joint count; ≥ 100% improvement in swollen joint count; and ≥ 100% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Disability Index of the Health Assessment Questionnaire
Acute phase reactant value (C-reactive protein).</description>
        <time_frame>Baseline, Week 26</time_frame>
        <population>Intent-to-Treat population; participants with a missing response were imputed as non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA + 2.5 mg MTX</title>
            <description>2.5 mg methotrexate (MTX) oral capsule weekly with 40 mg adalimumab (ADA) subcutaneous (SC) injection every other week (EOW) for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>ADA + 5 mg MTX</title>
            <description>5 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>ADA + 10 mg MTX</title>
            <description>10 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
          <group group_id="O4">
            <title>ADA + 20 mg MTX</title>
            <description>MTX oral capsule dose escalation from 10 mg to 20 mg in 2.5 mg increments every other week (10 mg x 2 weeks, 12.5 mg x 2 weeks, 15 mg x 2 weeks, 17.5 mg x 2 weeks), then 20 mg for 18 weeks with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With American College of Rheumatology (ACR) 100 Criteria Response at Week 26</title>
          <description>Response, as defined by ACR 100 criteria at Week 26. A participant is a responder if the following 3 criteria for improvement from Baseline are met: ≥ 100% improvement in tender joint count; ≥ 100% improvement in swollen joint count; and ≥ 100% improvement in at least 3 of the 5 following parameters:
Physician global assessment of disease activity
Patient global assessment of disease activity
Patient assessment of pain
Disability Index of the Health Assessment Questionnaire
Acute phase reactant value (C-reactive protein).</description>
          <population>Intent-to-Treat population; participants with a missing response were imputed as non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="1.0"/>
                    <measurement group_id="O3" value="2.0"/>
                    <measurement group_id="O4" value="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 26</title>
        <description>The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of &lt; 0.5. Negative change from Baseline in the overall score indicates improvement.</description>
        <time_frame>Baseline, Week 26</time_frame>
        <population>Intent-to-Treat population with non-missing baseline and at least 1 non-missing post-baseline value (baseline is defined as the last non-missing value prior to the first dose of study drug); last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA + 2.5 mg MTX</title>
            <description>2.5 mg methotrexate (MTX) oral capsule weekly with 40 mg adalimumab (ADA) subcutaneous (SC) injection every other week (EOW) for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>ADA + 5 mg MTX</title>
            <description>5 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>ADA + 10 mg MTX</title>
            <description>10 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
          <group group_id="O4">
            <title>ADA + 20 mg MTX</title>
            <description>MTX oral capsule dose escalation from 10 mg to 20 mg in 2.5 mg increments every other week (10 mg x 2 weeks, 12.5 mg x 2 weeks, 15 mg x 2 weeks, 17.5 mg x 2 weeks), then 20 mg for 18 weeks with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 26</title>
          <description>The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of &lt; 0.5. Negative change from Baseline in the overall score indicates improvement.</description>
          <population>Intent-to-Treat population with non-missing baseline and at least 1 non-missing post-baseline value (baseline is defined as the last non-missing value prior to the first dose of study drug); last observation carried forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="96"/>
                <count group_id="O4" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.72" spread="0.664"/>
                    <measurement group_id="O2" value="-0.71" spread="0.717"/>
                    <measurement group_id="O3" value="-0.78" spread="0.647"/>
                    <measurement group_id="O4" value="-0.82" spread="0.698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) ≤ –0.22 at Week 26</title>
        <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. The minimal clinically important difference (MCID) defined for the HAQ-DI is a change from Baseline of ≥ 0.22. HAQ remission indicating normal physical function is defined by HAQ-DI score of &lt; 0.5. Negative change from Baseline in the overall score indicates improvement.</description>
        <time_frame>Baseline, Week 26</time_frame>
        <population>Intent-to-Treat population; participants with a missing response were imputed as non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA + 2.5 mg MTX</title>
            <description>2.5 mg methotrexate (MTX) oral capsule weekly with 40 mg adalimumab (ADA) subcutaneous (SC) injection every other week (EOW) for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>ADA + 5 mg MTX</title>
            <description>5 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>ADA + 10 mg MTX</title>
            <description>10 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
          <group group_id="O4">
            <title>ADA + 20 mg MTX</title>
            <description>MTX oral capsule dose escalation from 10 mg to 20 mg in 2.5 mg increments every other week (10 mg x 2 weeks, 12.5 mg x 2 weeks, 15 mg x 2 weeks, 17.5 mg x 2 weeks), then 20 mg for 18 weeks with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) ≤ –0.22 at Week 26</title>
          <description>The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. The minimal clinically important difference (MCID) defined for the HAQ-DI is a change from Baseline of ≥ 0.22. HAQ remission indicating normal physical function is defined by HAQ-DI score of &lt; 0.5. Negative change from Baseline in the overall score indicates improvement.</description>
          <population>Intent-to-Treat population; participants with a missing response were imputed as non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.4"/>
                    <measurement group_id="O2" value="70.0"/>
                    <measurement group_id="O3" value="73.7"/>
                    <measurement group_id="O4" value="77.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Modified Total Sharp Score (mTSS) at Week 26</title>
        <description>The modified Total Sharp Score (mTSS) is a measure of change in joint health from digitized images of radiographs of hands and feet. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.</description>
        <time_frame>Baseline, Week 26</time_frame>
        <population>Intent-to-Treat population with available data at time point (observed cases).</population>
        <group_list>
          <group group_id="O1">
            <title>ADA + 2.5 mg MTX</title>
            <description>2.5 mg methotrexate (MTX) oral capsule weekly with 40 mg adalimumab (ADA) subcutaneous (SC) injection every other week (EOW) for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>ADA + 5 mg MTX</title>
            <description>5 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>ADA + 10 mg MTX</title>
            <description>10 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
          <group group_id="O4">
            <title>ADA + 20 mg MTX</title>
            <description>MTX oral capsule dose escalation from 10 mg to 20 mg in 2.5 mg increments every other week (10 mg x 2 weeks, 12.5 mg x 2 weeks, 15 mg x 2 weeks, 17.5 mg x 2 weeks), then 20 mg for 18 weeks with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Modified Total Sharp Score (mTSS) at Week 26</title>
          <description>The modified Total Sharp Score (mTSS) is a measure of change in joint health from digitized images of radiographs of hands and feet. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.</description>
          <population>Intent-to-Treat population with available data at time point (observed cases).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="95"/>
                <count group_id="O4" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="5.62"/>
                    <measurement group_id="O2" value="0.3" spread="1.92"/>
                    <measurement group_id="O3" value="0.4" spread="3.17"/>
                    <measurement group_id="O4" value="0.2" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With No Radiographic Progression at Week 26</title>
        <description>“No radiographic progression” was defined as a change from Baseline in modified Total Sharp Score (mTSS) at Week 26 of ≤ 0.5. mTSS is a measure of change in joint health from digitized images of radiographs of hands and feet. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.</description>
        <time_frame>Baseline, Week 26</time_frame>
        <population>Intent-to-Treat population; participants with a missing response were imputed as non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA + 2.5 mg MTX</title>
            <description>2.5 mg methotrexate (MTX) oral capsule weekly with 40 mg adalimumab (ADA) subcutaneous (SC) injection every other week (EOW) for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>ADA + 5 mg MTX</title>
            <description>5 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>ADA + 10 mg MTX</title>
            <description>10 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
          <group group_id="O4">
            <title>ADA + 20 mg MTX</title>
            <description>MTX oral capsule dose escalation from 10 mg to 20 mg in 2.5 mg increments every other week (10 mg x 2 weeks, 12.5 mg x 2 weeks, 15 mg x 2 weeks, 17.5 mg x 2 weeks), then 20 mg for 18 weeks with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With No Radiographic Progression at Week 26</title>
          <description>“No radiographic progression” was defined as a change from Baseline in modified Total Sharp Score (mTSS) at Week 26 of ≤ 0.5. mTSS is a measure of change in joint health from digitized images of radiographs of hands and feet. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 [normal] to 398 [maximal disease]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.</description>
          <population>Intent-to-Treat population; participants with a missing response were imputed as non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.3"/>
                    <measurement group_id="O2" value="72.0"/>
                    <measurement group_id="O3" value="76.8"/>
                    <measurement group_id="O4" value="77.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Simplified Disease Activity Index (SDAI) Remission at Week 26</title>
        <description>SDAI is a measure of disease activity derived as follows: SDAI = SJC28 + TJC28 + GH (cm) + PhGA (cm) + CRP (mg/dL), where TJC28 and SJC28 represent total tender joint count and total swollen joint count, respectively, based on 28 joints (including the left and right side of the body), GH = Patient's Global Assessment of Disease Activity, and PhGA = Physician's Global Assessment of Disease Activity (both measured on a visual analogue scale with a range of 0 [none] to 10 [severe]), and CRP is C-reactive protein measured in mg/dL. SDAI total score = 0 to 86. SDAI ≤ 3.3 indicates disease remission, &gt; 3.4 to 11 = low disease activity, &gt; 11 to 26 = moderate disease activity, and &gt; 26 = high disease activity.</description>
        <time_frame>Week 26</time_frame>
        <population>Intent-to-Treat population; participants with a missing response were imputed as non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA + 2.5 mg MTX</title>
            <description>2.5 mg methotrexate (MTX) oral capsule weekly with 40 mg adalimumab (ADA) subcutaneous (SC) injection every other week (EOW) for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>ADA + 5 mg MTX</title>
            <description>5 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>ADA + 10 mg MTX</title>
            <description>10 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
          <group group_id="O4">
            <title>ADA + 20 mg MTX</title>
            <description>MTX oral capsule dose escalation from 10 mg to 20 mg in 2.5 mg increments every other week (10 mg x 2 weeks, 12.5 mg x 2 weeks, 15 mg x 2 weeks, 17.5 mg x 2 weeks), then 20 mg for 18 weeks with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Simplified Disease Activity Index (SDAI) Remission at Week 26</title>
          <description>SDAI is a measure of disease activity derived as follows: SDAI = SJC28 + TJC28 + GH (cm) + PhGA (cm) + CRP (mg/dL), where TJC28 and SJC28 represent total tender joint count and total swollen joint count, respectively, based on 28 joints (including the left and right side of the body), GH = Patient's Global Assessment of Disease Activity, and PhGA = Physician's Global Assessment of Disease Activity (both measured on a visual analogue scale with a range of 0 [none] to 10 [severe]), and CRP is C-reactive protein measured in mg/dL. SDAI total score = 0 to 86. SDAI ≤ 3.3 indicates disease remission, &gt; 3.4 to 11 = low disease activity, &gt; 11 to 26 = moderate disease activity, and &gt; 26 = high disease activity.</description>
          <population>Intent-to-Treat population; participants with a missing response were imputed as non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2"/>
                    <measurement group_id="O2" value="22.0"/>
                    <measurement group_id="O3" value="28.3"/>
                    <measurement group_id="O4" value="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinical Disease Activity Index (CDAI) Remission at Week 26</title>
        <description>CDAI is a measure of disease activity derived as follows: CDAI = SJC28 + TJC28 + GH (cm) + PhGA (cm) where TJC28 and SJC28 represent total tender joint count and total swollen joint count, respectively, based on 28 joints (including the left and right side of the body), GH = Patient's Global Assessment of Disease Activity, and PhGA = Physician's Global Assessment of Disease Activity (both measured on a visual analogue scale with a range of 0 [none] to 10 [severe]). CDAI total score = 0 to 76. CDAI ≤ 2.8 indicates disease remission, &gt; 2.8 to 10 = low disease activity, &gt; 10 to 22 = moderate disease activity, and &gt; 22 = high disease activity.</description>
        <time_frame>Week 26</time_frame>
        <population>Intent-to-Treat population; participants with a missing response were imputed as non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>ADA + 2.5 mg MTX</title>
            <description>2.5 mg methotrexate (MTX) oral capsule weekly with 40 mg adalimumab (ADA) subcutaneous (SC) injection every other week (EOW) for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>ADA + 5 mg MTX</title>
            <description>5 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>ADA + 10 mg MTX</title>
            <description>10 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
          <group group_id="O4">
            <title>ADA + 20 mg MTX</title>
            <description>MTX oral capsule dose escalation from 10 mg to 20 mg in 2.5 mg increments every other week (10 mg x 2 weeks, 12.5 mg x 2 weeks, 15 mg x 2 weeks, 17.5 mg x 2 weeks), then 20 mg for 18 weeks with 40 mg ADA SC injection EOW for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Disease Activity Index (CDAI) Remission at Week 26</title>
          <description>CDAI is a measure of disease activity derived as follows: CDAI = SJC28 + TJC28 + GH (cm) + PhGA (cm) where TJC28 and SJC28 represent total tender joint count and total swollen joint count, respectively, based on 28 joints (including the left and right side of the body), GH = Patient's Global Assessment of Disease Activity, and PhGA = Physician's Global Assessment of Disease Activity (both measured on a visual analogue scale with a range of 0 [none] to 10 [severe]). CDAI total score = 0 to 76. CDAI ≤ 2.8 indicates disease remission, &gt; 2.8 to 10 = low disease activity, &gt; 10 to 22 = moderate disease activity, and &gt; 22 = high disease activity.</description>
          <population>Intent-to-Treat population; participants with a missing response were imputed as non-responders.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2"/>
                    <measurement group_id="O2" value="22.0"/>
                    <measurement group_id="O3" value="29.3"/>
                    <measurement group_id="O4" value="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events and serious adverse events, defined as those that began after the first dose of study drug, but within 70 days after the last dose of study drug. Duration of treatment was 24 weeks for ADA and 25 weeks for MTX.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ADA + 2.5 mg MTX</title>
          <description>2.5 mg methotrexate (MTX) oral capsule weekly with 40 mg adalimumab (ADA) subcutaneous (SC) injection every other week (EOW) for 26 weeks</description>
        </group>
        <group group_id="E2">
          <title>ADA + 5 mg MTX</title>
          <description>5 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
        </group>
        <group group_id="E3">
          <title>ADA + 10 mg MTX</title>
          <description>10 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks</description>
        </group>
        <group group_id="E4">
          <title>ADA + 20 mg MTX</title>
          <description>MTX oral capsule dose escalation from 10 mg to 20 mg in 2.5 mg increments every other week (10 mg x 2 weeks, 12.5 mg x 2 weeks, 15 mg x 2 weeks, 17.5 mg x 2 weeks), then 20 mg for 18 weeks with 40 mg ADA SC injection EOW for 26 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>COLITIS ULCERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>INTERVERTEBRAL DISC DEGENERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>RHEUMATOID ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie (prior sponsor, Abbott)</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

